Edition:
India

Ultragenyx Pharmaceutical Inc (RARE.OQ)

RARE.OQ on NASDAQ Stock Exchange Global Select Market

48.18USD
2:29am IST
Change (% chg)

$1.06 (+2.25%)
Prev Close
$47.12
Open
$47.04
Day's High
$50.76
Day's Low
$47.04
Volume
366,020
Avg. Vol
210,722
52-wk High
$91.17
52-wk Low
$41.68

Chart for

About

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody... (more)

Overall

Beta: 1.86
Market Cap(Mil.): $2,305.92
Shares Outstanding(Mil.): 42.46
Dividend: --
Yield (%): --

Financials

BRIEF-Ultragenyx Reports Q4 Loss Per Share $1.89

* ULTRAGENYX REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE

2:44am IST

BRIEF-Ultragenyx Prices Public Offering Of 4.39 Mln Common Shares At $57/Share

* ULTRAGENYX ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Ultragenyx Announces Proposed Public Offering Of Common Stock

* ULTRAGENYX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

23 Jan 2018

BRIEF-Capital International Investors Reports 10.3 Pct Passive Stake In Ultragenyx

* CAPITAL INTERNATIONAL INVESTORS REPORTS 10.3 PERCENT PASSIVE STAKE IN ULTRAGENYX PHARMACEUTICAL INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text for Eikon: (http://bit.ly/2D1HymY) Further company coverage:

11 Jan 2018

BRIEF-Ultragenyx Announces Update To UX007 Development Program In Long-Chain Fatty Acid Oxidation Disorder Patients

* ULTRAGENYX ANNOUNCES UPDATE TO UX007 DEVELOPMENT PROGRAM IN LONG-CHAIN FATTY ACID OXIDATION DISORDER PATIENTS

04 Jan 2018

BRIEF-Ultragenyx Sells Priority Review Voucher For $130 Mln

* ENTERED INTO A DEFINITIVE AGREEMENT TO SELL ITS RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER TO NOVARTIS Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-Ultragenyx And Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion For Treatment Of X-Linked Hypophosphatemia In Children

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE BUROSUMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF X-LINKED HYPOPHOSPHATEMIA IN CHILDREN

15 Dec 2017

BRIEF-Ultragenyx And Kyowa Kirin Announce Positive 48-Week Data From Adult Phase 3 Study Of Burosumab In X-Linked Hypophosphatemia

* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE POSITIVE 48-WEEK DATA FROM ADULT PHASE 3 STUDY OF BUROSUMAB (KRN23) IN X-LINKED HYPOPHOSPHATEMIA Source text for Eikon: Further company coverage:

04 Dec 2017

BRIEF-Ultragenyx completes patients dosing in first cohort of phase 1/2 study of DTX301

* Ultragenyx announces completion of patient dosing in first cohort of phase 1/2 clinical study of dtx301 gene therapy in ornithine transcarbamylase (OTC) deficiency

16 Nov 2017

BRIEF-ULTRAGENYX SAYS FDA APPROVES MEPSEVII FOR GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

* ULTRAGENYX ANNOUNCES FDA APPROVAL OF MEPSEVII™ (VESTRONIDASE ALFA), THE FIRST THERAPY FOR PROGRESSIVE AND DEBILITATING RARE GENETIC DISEASE MUCOPOLYSACCHARIDOSIS VII

16 Nov 2017

Earnings vs. Estimates